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Abstract  The  management  of  colorectal  intrahepatic  metastases  before  resection  is  multi-
disciplinary  and  radiologists  and  nuclear  medicine  specialists  play  a  major  role.  In  accordance
with the  French  National  Guide  for  appropriate  use  of  diagnostic  imaging,  the  approach
should be  multimodal:  a  chest-abdomen  and  pelvic  (CAP)  CT  scan  and  hepatic  MRI  are  manda-
tory while  PET-CT  provides  important  additional  information,  in  particular  on  intra-abdominal
extrahepatic  metastases.  This  multimodal  approach  emphasizes  the  importance  of  early  and
appropriate  use  of  imaging  in  these  patients,  as  well  as  the  central  role  of  multidisciplinary
meetings  in  oncology.
© 2014  Éditions  françaises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
The  prognosis  of  patients  with  colorectal  cancer  is  dependent  upon  the  presence  or  not
of  metastases,  in  particular  in  the  liver.  These  hepatic  metastases  are  found  in  20  to  70%
of  patients  [1]  and  they  are  intrahepatic  alone  in  approximately  30%  of  the  cases.  It  is  now
generally  accepted  that  local  treatment  of  liver  metastases  associated  with  perioperative
adjuvant  therapy  improves  recurrence-free  survival  as  well  as  overall  survival  [2—4].  In  this
∗ Corresponding author.
E-mail address: alain.luciani@hmn.aphp.fr (A. Luciani).
http://dx.doi.org/10.1016/j.diii.2014.03.007
2211-5684/© 2014 Éditions franc¸aises de radiologie. Published by Elsevier Masson SAS. All rights reserved.
5c
m
t
r
I
a
g
m
t
I
r
c
S
p
i
(
t
T
u
p
s
p
C
o
r
[
2
C
w
s
(
W
m
m
P
p
F
M
i
C
m
e
p
s
o
C
m
c
t
p
i
s
g
l
d
s
A
s
e
o
t
b
1
e
p
b
s
t
P
m
p
r
a
t
a
metastatic  colorectal  cancers  eligible  for  surgical  resection06  
ontext,  the  goal  of  imaging  before  resection  is  to  detect  all
etastatic  tumors  and  identify  their  location,  to  determine
he  feasibility  of  local  resection,  as  well  as  to  evaluate  the
esponse  to  possible  adjuvant  therapy  and  assess  its  toxicity.
ndeed,  the  risk  of  morbidity  from  preoperative  chemother-
py  is  known  [5].
The  goal  of  this  article  is  to  describe  the  existing
uidelines  for  imaging  before  resection  of  colorectal  liver
etastases,  then  suggest  the  optimal  imaging  strategy  in
his  context.
maging techniques to determine the
esectability of liver metastases:
omparison of diagnostic values
everal  meta-analyses  have  compared  ultrasound,  com-
uted  tomography  (CT  scan),  magnetic  resonance  imag-
ng  (MRI),  ﬂuodeoxyglucose-positron  emission  tomography
FDG-PET)  and  positron  emission  tomography-computed
omography  (PET-CT)  for  the  diagnosis  of  liver  metastases.
he  ﬁrst  meta-analysis  published  by  Kinkel  et  al.  [6]  eval-
ated  111  studies  including  nine  ultrasound  studies  (509
atients),  25  CT  scan  studies  (1747  patients),  11  MRI  based
tudies  (401  patients)  and  nine  PET  scan  studies  (423
atients),  with  sensitivities  of  55%  for  ultrasound,  72%  for
T  scan,  76%  for  MRI  and  90%  for  FDG-PET;  the  speciﬁcity
f  the  different  modes  was  equivalent.  These  results  were
ecently  modiﬁed  by  the  study  published  by  Floriani  et  al.
7],  based  on  a  review  of  6030  articles  and  an  evaluation  of
5  speciﬁc  studies:  the  sensitivity  of  ultrasound  was  63—97%,
T  scan  was  74.8—95.6%,  MRI  was  80.1—97.2%,  and  FDG-PET
as  93.8-98.7%.  MRI  seemed  to  be  more  sensitive  than  CT
can  in  this  study,  both  per  patient  and  per  lesion  analysis
Fig.  1).
hat is  the role of PET scan in the
anagement of colorectal cancer liver
etastases before resection?ET  scan  plays  an  important  role  in  the  management  of
atients  with  colorectal  cancer  before  resection.  In  a  study
igure 1. a: axial contrast enhanced portal phase CT scan of the live
RI (b = 100 sec/mm2): discovery of an additional metastasis in segment
c
s
aF.  Legou  et  al.
n  2007  including  131  patients,  75  with  colorectal  cancer,
hua  et  al.  [8]  suggested  that  patient  management  had  been
odiﬁed  because  of  PET  scan  results  in  25%  of  patients.  How-
ver,  this  study  was  based  on  a  5  year  follow-up  and  the
arameters  used  to  compare  CT  scan  acquisitions  and  PET
can  varied  with  CT-slice  collimation  ranging  from  4  ×  1  mm
r  4  ×  2.5  mm.  Moreover,  as  in  several  studies  including  PET-
T,  there  was  no  reference  test  to  evaluate  lesions  that  were
issed  on  CT  scan  but  positive  on  PET  scan,  which  con-
erned,  in  particular,  extrahepatic  lesions.  Researchers  at
he  CHRU  Lille  [9]  evaluated  lesions  that  were  found  to  be
ositive  on  PET  scan  and  were  not  detected  by  other  imag-
ng  techniques.  The  authors  performed  a  preoperative  PET
can  and  CT  scan  in  a  series  of  53  patients  who  were  eli-
ible  for  resection  of  colorectal  hepatic  metastases,  with
ess  than  61  days  between  the  two  imaging  tests  (mean  24
ays).  All  lesions  detected  by  imaging  were  investigated
urgically  providing  an  extensive  pathological  correlation.
 total  of  119  tumoral  metastases  were  detected  in  the
tudy  population.  There  was  disagreement  between  preop-
rative  imaging  and  the  surgical  results  in  37/119  lesions,
r  31%  of  the  cases:  26  cases  of  disagreement  involved
he  liver  and  an  identical  number  of  lesions  were  missed
y  PET  scan  and  CT  scan  including  nine  lesions  less  than
 cm  that  were  missed  on  PET  scan.  Disagreement  involved
xtrahepatic  abdominal  lesions  in  11  cases,  in  particular
eritoneal  carcinomatosis  most  of  which  (6/8)  were  missed
y  CT  scan,  while  a  greater  number  were  detected  by  PET
can.  None  of  the  thoracic  lesions  were  missed  by  either  of
he  imaging  techniques.  Overall,  the  authors  reported  that
ET  scan  had  a  deﬁnite  positive  inﬂuence  in  the  manage-
ent  of  ﬁve  patients  (or  9%  of  the  cases),  but  with  false
ositives  in  three  patients  (6%  of  the  cases),  in  particular
egarding  the  characterization  of  a mediastinal  adenopathy
nd  two  bone  lesions  that  were  not  conﬁrmed  as  metas-
ases.
The  authors  of  a  recent  prospective  study  [10]  evalu-
ting  the  preoperative  imaging  strategies  in  patients  withr hows the presence of two metastases (thin arrows); b: diffusion
 2 (arrowhead).
onﬁrmed  the  following:  the  study  concluded  that  CT
can  and  MRI  should  be  performed  for  the  preoperative
ssessment  of  patients  with  suspected  colorectal  cancer
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Figure 2. a: contrast enhanced portal venous phase CT scan of the liver: round lesion in segment 4b, measuring 2.9 cm (thick arrow); b:
after targeted chemotherapy, the lesion is smaller measuring 1.4 cm; it is hypermetabolic on PET scan (thin arrow); c: it is also detected by
portal venous phase CT scan (arrow); d: the lesion shows hypersignal intensity on diffusion MRI (b = 100 sec/mm2) (arrow); e: this hypersignal
persists at b = 800 sec/mm2 (arrow); f: The lesion shows restricted ADC (low intensity on ADC map: red arrow); g: the lesion shows peripheral
contrast enhancement during the portal venous phase (arrow); h—i: note the presence of liver steatosis caused by chemotherapy (signal
dropout during the out phase (i) compared to the in phase (h) sequence (arrow head). (For interpretation of the references to colour in this
ﬁgure legend, the reader is referred to the web version of this article).
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aigure 2. (Continued)
etastases,  and  suggested  that  the  role  of  PET  scan  was
specially  important  for  detecting  potentially  resectable
ntraabdominal,  extrahepatic  metastases  (Fig.  2).  More
ecently  in  a  retrospective  study,  Ayez  et  al.  [11]  suggested
hat  whatever  inﬂuence  PET-CT  had  on  the  detection  of
etastases  before  resection,  this  did  not  inﬂuence  sur-
ival  without  progression  or  overall  survival.  Determining
he  inﬂuence  of  technical  improvements  in  morphologi-
al,  functional  and  metabolic  imaging  on  overall  patient
urvival  in  prospective  studies,  is,  in  fact,  a  major  chal-
enge.
In  any  case,  it  is  important  to  remember  that  preop-
rative  PET-CT  should  not  be  performed  for  the  resection
f  hepatic  metastases  less  than  a  month  after  the  last
hemotherapy  session.  A  PET  scan  that  is  performed  ear-
ier  is  an  important  source  of  false  negatives,  which  can
each  86.7%,  as  shown  in  the  study  by  Glazer  el  al.  [12]
Fig.  3).
hy is MRI so important?
he  optimization  of  MRI  technology  is  constantly
rogressing
esides  the  development  of  parallel  reconstruction  and
ynamic  acquisitions  with  millimetric  slices,  in  the  past
0  years  the  detection  and  characterization  of  intrahepatic
a
a
o
aetastases  with  MRI  have  improved  thanks  to  two  important
echnological  advancements.  These  are  diffusion  weighted
RI  and  the  use  of  hepatocyte-speciﬁc  contrast  agents.  The
se  of  these  two  techniques,  independently  or  combined,
rovides  more  sensitive,  speciﬁc  and  accurate  character-
zation  of  liver  metastases  [13,14]  (Fig.  2).  In  a  recent
tudy,  Chung  et  al.  evaluated  the  inﬂuence  of  the  use  of
 hepatocyte-speciﬁc  contrast  agents  including  iron  oxide
articles  and  gadoxetic  acid  (gadolinium  EOB-DPTA,  Primo-
ist,  Bayer),  which  both  increase  contrast  enhancement
etween  metastases  and  the  underlying  liver  [15]. There
as  no  difference  in  accuracy,  sensitivity  or  the  positive  pre-
ictive  value  of  these  two  contrast  agents  for  metastases
arger  than  10  mm.  On  the  other  hand,  the  use  of  these
gents,  and  in  particular  gadolinium  EOB-DPTA,  increased
he  accuracy  and  sensitivity  for  metastases  smaller  than
0  mm.  These  results  were  recently  conﬁrmed  in  the  study
y  Koh  et  al.  [16]  This  team  included  417  lesions  including
07  benign  lesions  and  310  colorectal  cancer  metastases  in
2  patients,  and  compared  the  impact  of  diffusion  weighted
RI  and  gadolinium  EOB-DTPA  contrast  enhanced  imaging
s  well  as  the  combined  reading—of  diffusion  and  hep-
tocyte  phase  after  gadolinium  EOB-DTPA  injection.  The
uthors  reported  that  the  combined  use  of  diffusion  MRI  and
 hepatocyte-speciﬁc  contrast  agent  increases  detection
f  lesions  because  the  use  of  hepatocyte-speciﬁc  contrast
gents  helps  in  detecting  a  certain  number  of  lesions  in
Imaging  strategies  before  beginning  treatment  of  colorectal  liver  metastases  509
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he  left  lobe  that  are  missed  with  diffusion  imaging  owing
o  heartbeat  artifacts.  Hence,  three  lesions  were  missed
2%  of  all  lesions)  by  one  of  the  observers  using  combined
iffusion  imaging  and  hepatocyte-speciﬁc  contrast  enhance-
ent,  compared  to  26  (13%)  using  diffusion  imaging  alone  as
ell  as  other  MRI  sequences.
he  inﬂuence  of  chemotherapy  on  imaging
echniques:  the  superiority  of  MRI
esides  improvements  in  MRI  technology,  chemotherapies
re  known  to  signiﬁcantly  modify  the  underlying  liver
arenchyma,  either  because  of  vascular  modiﬁcations  or
epatic  steatosis  [17—21]  (Fig.  2  H,  I).
In  a  meta-analysis  by  Van  Kessel  et  al.  [22],  11  stud-
es  including  223  patients  and  906  colorectal  cancer  liver
etastases  were  evaluated.  The  authors  studied,  in  partic-
lar,  the  inﬂuence  of  neoadjuvent  chemotherapy  on  imaging
esults.  The  sensitivity  of  MRI  in  case  of  prior  chemotherapy
as  more  than  72%,  while  it  was  no  more  than  63.4%  for
DG-PET.  Thus,  adjuvant  chemotherapy  signiﬁcantly  inﬂu-
nces  the  efﬁcacy  of  PET-CT.  This  inﬂuence  was  less  marked
n  CT  scan  results,  even  if  liver  steatosis  also  reduces  the
ensitivity  of  CT  scan  for  accurate  detection  of  all  lesions.
hat can be expected from PET-MRI under
hese conditions?
linical  studies  on  hybrid  PET-MRI  imaging  for  the  manage-
ent  of  liver  metastases  have  just  begun.  In  a  recent  study,
atalano  et  al.  [23]  compared  the  results  of  simultaneous
ET-MRI  and  PET-CT  for  the  detection  of  metastases.  PET-
RI  seemed  to  detect  additional  lesions  in  41%  of  patients,
hich  had  a  direct  clinical  impact  on  patient  management
n  17.9%  of  all  cases  (or  24  patients)  unlike  PET-CT.  This
as  especially  true  for  the  elimination  of  certain  malig-
ant  lesions,  the  incidental  discovery  of  other  cancers,  the
etection  of  adenopathies  or  the  conﬁrmation  of  malignant
one  lesions.  Beiderwellen  et  al.  [24]  also  compared  the
ole  of  PET-MRI  to  PET-CT  in  70  patients  presenting  with
rimary  tumors  (including  four  colorectal  cancers).  Char-
cterization  of  tumors  seemed  to  be  better  with  PET-MRI
n  particular  intrahepatic  lesions,  but  because  of  the  few
umber  of  included  patients  these  data  are  preliminary.
einer  et  al.  [25]  suggested  that  the  diagnostic  accuracy
as  better  with  use  of  T1-  and  T2-weighted  sequences  com-
ined  with  PET-MRI  than  with  PET-CT  and  could  therefore
lay  a  diagnostic  role  in  the  process  of  patient  manage-
ent.  These  preliminary  data  suggest  that  the  combination
f  metabolic  imaging,  which  effectively  detects  intraabdom-
nal  extrahepatic  lesions  and  MRI  which  effectively  detects
nd  characterizes  intrahepatic  metastases,  could  play  an
mportant  role  in  the  future  in  the  management  of  patients
ho  are  eligible  for  resection.  The  problem  of  detecting  and
o
C
p
‘
igure 3. a: portal venous phase contrast enhanced liver CT scan: ne
thick arrow); b: a second hypodense lesion on CT scan is visible in segm
esions (arrows); d: both lesions are hypermetabolic on PET-CT (arrows); 
nhanced MRI (circle); f: this third lesion was not seen on CT scan or PEF.  Legou  et  al.
haracterizing  pulmonary  nodules  still  seems  to  be  better
ith  CT  scan.
anagement guidelines
uidelines for appropriate use of diagnostic
maging
he  guide  for  appropriate  use  of  diagnostic  imaging  by
he  French  Health  Authority  (Haute  Autorité  de  santé
HAS]),  associated  with  the  French  Society  of  Radiology
nd  the  French  Society  of  Nuclear  Medicine  has  drafted
he  imaging  strategy  before  resection  of  colorectal  cancer
epatic  metastases.  Three  tests  are  recommended  in  this
peciﬁc  clinical  context:  MRI  of  the  liver,  chest-abdomen-
elvic  (CAP)  CT  scan  and  PET-  CT  combined  with  the  use  of
DG  (gbu.radiologie.fr).
These  guidelines  are  similar  to  the  consensus  opin-
on  proposed  by  Adams  et  al.  [26],  which  recommends
RI  as  the  ﬁrst  line  test  in  this  clinical  situation.  These
xperts  note  that  this  is  especially  important  for  lesions
ess  than  1  cm  whose  detection  is  improved  by  diffusion
RI  and  hepatocyte  directed  contrast  enhancement  but
lso  in  case  of  steatosis  after  chemotherapy  where  MRI
eems  to  perform  better  than  other  imaging  techniques.
he  experts  concluded  that  PET-CT  is  useful  for  iden-
ifying  intraabdominal  extrahepatic  metastases,  but  not
ntrathoracic  lesions  or  intrahepatic  lesions  smaller  than
 cm.
anagement strategy
s  we  have  seen  MRI,  PET-CT  and  CT  scan  are  indicated
efore  resection  of  colorectal  hepatic  metastases,  each  for
ifferent  purposes  of  detection  and  characterization.  At
resent,  MRI  is  the  technique  that  provides  optimal  detec-
ion  of  intrahepatic  metastases.
Overall  patient  management  could  be  modiﬁed  in
elation  to  these  elements.  MRI  of  the  liver  could  be  recom-
ended  during  initial  management  to  optimize  comparison
ith  post-chemotherapy  MRI.  Indeed,  only  comparative
ests  with  the  same  imaging  technique  can  provide  an
ccurate  assessment  of  lesions.  Communication  between
he  oncologist,  the  liver  surgeon  and  the  radiologist
s  essential.  Eligibility  for  curative  resection  is  usually
ecided  during  multidisciplinary  meetings  in  specialized
enters.
Under  these  conditions,  at  baseline,  all  patients  poten-
ially  resectable  could  undergo  a liver  MRI  and  an  FDG
ETCT,  as  well  as  a  CAP  CT  scan,  so  that  the  progression
r  response  to  treatment  could  then  be  monitored  based  on
T  scan  results  [27], while  pre-resection  MRIs  could  be  com-
ared  to  initial  MRIs,  to  limit  the  number  of  metastases  that
‘disappear’’.
crotic mass, with ﬁbrous enhancement centered on segments 2—4
ent 7 (thin arrow); c: MRI shows peripheral enhancement of both
e: discovery of an additional lesion on portal venous phase contrast
T-CT (circle).
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Conclusion
Patient  management  before  resection  of  intrahepatic
metastases  is  multidisciplinary  with  radiologists  and  nuclear
medicine  specialists  playing  an  important  role.  CAP  CT
scan  and  MRI  of  the  liver  are  essential.  PET-CT  pro-
vides  important  information  especially  on  intraabdominal,
extrahepatic  metastases.  The  development  of  PET-MRI
will  probably  inﬂuence  the  future  management  of  these
patients.
TAKE-HOME  MESSAGES
• MRI  is  the  ﬁrst  line-imaging  test  for  intrahepatic
metastases.
• All  patients  with  intrahepatic  metastases  should  be
considered  as  potential  candidates  for  resection.
• A  liver  MRI  as  well  as  CAP  CT  scan  should  be
recommended  at  the  beginning  of  the  patient
management  process  enabling  the  comparison  with
pre-resection  MRI
• PET-CT  is  indicated  in  the  pre-resection  assessment
of  liver  metastases.
• PET-CT  is  useful  in  particular  for  the  detection  of
intraabdominal  extra-hepatic  locations.
• There  must  be  a  4-week  delay  between  the  end  of
chemotherapy  and  the  PET-CT  examination.
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